心脏收缩性调制疗法的基础科学:分子和电生理学机制
Daniele Masarone1, Michelle M Kittleson2, Antonio D'Onofrio3
1Heart Failure Unit, Department of Cardiology, AORN dei Colli/Monaldi Hospital, Naples, Italy.
Heart rhythm
|September 28, 2023
概括
心脏收缩性调制疗法对心力衰竭与减少喷射率 (HFrEF) 和心力衰竭与保存喷射率 (HFpEF) 的治疗有希望. 这种基于设备的疗法对细胞功能产生了积极的影响,并减少了心肌衰竭中的纤维化.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 分子心脏病学分子心脏病学
背景情况:
- 减少喷射分数 (HFrEF) 的心力衰竭和保存喷射分数 (HFpEF) 的心力衰竭涉及心肌中显著的细胞和分子变化.
- 这些变化包括处理受损,新陈代谢效率低下,胎儿基因重新激活,改变的电生理学和心肌纤维化.
研究的目的:
- 在HFrEF和HFpEF中审查心脏收缩度调制 (CCM) 治疗的临床前文献.
- 为了将CCM的分子和电生理效应与观察到的临床益处相关联.
主要方法:
- 对研究CCM治疗的临床前研究的综述.
- 分析CCM诱导的细胞和分子变化.
- 在HFrEF和HFpEF模型中,CCM影响与临床结果的相关性.
主要成果:
- 在HFrEF中,CCM疗法已经证明能够恢复的处理和改善肌细胞代谢状态.
- 已经证明,CCM可以逆转胎儿基因程序,并减少心脏衰竭中的间歇性纤维化.
- CCM正在对HFpEF进行调查,临床前数据表明潜在的益处.
结论:
- 心脏收缩性调制疗法通过解决关键的细胞和分子乱,为治疗心力衰竭提供了一种新的方法.
- 临床前证据支持CCM在改善HFrEF和潜在的HFpEF心脏功能和结构方面的有效性.
相关概念视频
Pathophysiology of Cardiac Performance
694
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
694
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Mechanism of Cardiac Arrhythmias
943
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
943
Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Electrophysiology of Normal Cardiac Rhythm
5.6K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
5.6K


